Recently, Micro-Way Inter-Innovation Medical Technology (Shanghai) Co., Ltd. proudly announced the successful completion of its angel round financing, raising tens of millions of yuan. The investor for this round is Daotong Investment. This achievement marks the company's inaugural external funding since its inception in 2024.

The freshly raised capital will be strategically allocated to expand the range of indications for its flagship product, the wearable nerve stimulator. Additionally, it will fuel the progress of multi-center clinical trials and bolster the company's domestic and international market presence, with the overarching goal of propelling the industrialization of non-invasive brain-computer interface technology.

With a core focus on the integration of medicine and engineering, Micro-Way Medical has constructed a diverse product portfolio. Its cornerstone product, the wearable nerve stimulator, has already embarked on multi-center registered clinical trials and is projected to secure registration certification in the latter half of 2026.

The company takes pride in its elite, cross-disciplinary team and has established a comprehensive collaboration model that seamlessly integrates industry, academia, medicine, and engineering. Founder Chen Fen emphasized that this collaborative approach will expedite the product's market introduction. Industry analysts concur that this financing round signifies a pivotal moment in the company's growth trajectory and is poised to catalyze advancements in China's non-invasive neuromodulation sector. Looking ahead, Micro-Way Medical is well-positioned to secure a prominent foothold in the relevant market.